News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Callisto Pharmaceuticals Redirects Atiprimod Clinical Development to Treat Rheumatoid Arthritis


1/27/2009 9:52:31 AM

NEW YORK--(BUSINESS WIRE)--Callisto Pharmaceuticals, Inc. (OTC BB: CLSP.OB) today announced that it is focusing further development of atiprimod on treatment of rheumatoid arthritis (RA). Atiprimod has demonstrated a favorable clinical safety profile robustly supported by earlier RA studies as well as by recent oncology trials in advanced carcinoid cancer patients, where the drug was dosed at levels and frequencies considerably higher than anticipated for use in RA. Callisto believes that atiprimod holds significant promise as a new class of orally-administered, disease-modifying agent in RA.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES